Stay updated with breaking news from Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2... | March 23, 2023
22.11.2022 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will participate in a fireside chat at the ...
Item 2.02 Results of Operations and Financial Condition. On November 14, 2022, Alpine Immune Sciences, Inc. issued a press release reporting its financial results for the three and nine months... | November 14, 2022
News, features, and commentary about cancer-related issues
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade on Wednesday after recording losses on Tuesday. The Dow Jones...